| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites reduced: 278 -> 271 locations |
| 2026-06-04 | NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… |
date change Completion pushed: 2028-03-31 -> 2028-12-31 |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Recruitment opened |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Primary completion moved earlier: 2029-06-29 -> 2028-10-31 |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Completion pushed: 2032-12-31 -> 2033-01-31 |
| 2026-05-15 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites expanded: 131 -> 279 locations |
| 2026-05-14 | NCT05981209 Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-14 | NCT05981209 Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory… |
Enrollment reduced: 27 -> 12 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab… | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Multiple Myeloma | Recruiting |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… | Multiple Myeloma | Recruiting |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… | Multiple Myeloma | Recruiting |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| Phase 2 | |||
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell… | Multiple Myeloma in Relapse | Active, Not Recruiting |
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed… | Multiple Myeloma | Active, Not Recruiting |
| NCT04835129 | Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory… | Multiple Myeloma | Active, Not Recruiting |
| NCT02420860 | Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly… | Hematopoietic Cell Transplantation Recipient | Active, Not Recruiting |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Myelofibrosis Transformation in Essential Thrombocythemia | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | Active, Not Recruiting |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy… | Multiple Myeloma | Active, Not Recruiting |
| Phase 1 | |||
| NCT05981209 | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory… | Recurrent Multiple Myeloma | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for… | Multiple Myeloma | Active, Not Recruiting |